Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Neil Hounslow"'
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 8, Pp n/a-n/a (2024)
Abstract Elevated triglyceride levels are associated with an increased risk of cardiovascular events despite guideline‐based statin treatment of low‐density lipoprotein cholesterol. Peroxisome proliferator‐activated receptor α (PPARα) agonist
Externí odkaz:
https://doaj.org/article/1225612d91104b6084aa28e42916175f
Autor:
Peter J. Meikle, Gerard Wong, Ricardo Tan, Philippe Giral, Paul Robillard, Alexina Orsoni, Neil Hounslow, Dianna J. Magliano, Jonathan E. Shaw, Joanne E. Curran, John Blangero, Bronwyn A. Kingwell, M.John Chapman
Publikováno v:
Journal of Lipid Research, Vol 56, Iss 12, Pp 2381-2392 (2015)
The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese m
Externí odkaz:
https://doaj.org/article/bf4b199182dd429981dbd78ba91daec8
Publikováno v:
Drug Metabolism and Pharmacokinetics. 35:S35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a82ebcef3f86d6ac00cadcd35e92daa
https://doi.org/10.1016/j.dmpk.2020.04.048
https://doi.org/10.1016/j.dmpk.2020.04.048
Publikováno v:
Atherosclerosis Supplements. 32:156-157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52aaeae221883163d9ea1e7058cdcd0b
https://doi.org/10.1016/j.atherosclerosissup.2018.04.474
https://doi.org/10.1016/j.atherosclerosissup.2018.04.474
Publikováno v:
Clinical Pharmacology in Drug Development. 2:195-200
Itraconazole is a synthetic triazole antifungal agent which is known to be a potent inhibitor of cytochrome P450 (CYP) 3A4, and may cause drug-drug interactions with the many drugs metabolized by this route, including some statins. In this study, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9e448bf8bee62e166d41ccdfbec3271
https://doi.org/10.1002/cpdd.19
https://doi.org/10.1002/cpdd.19
Publikováno v:
Clinical Drug Investigation. 31:735-743
Background and Objectives: Pitavastatin is a highly effective lipid-lowering drug (approved dose range 1–4 mg/day) with a distinctive metabolic pathway that has a low potential for drug interactions. The efficacy and safety of pitavastatin have bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8aa5a7c8d0b4d81dae18c7ed09b34ee
https://doi.org/10.2165/11592480-000000000-00000
https://doi.org/10.2165/11592480-000000000-00000
Publikováno v:
Atherosclerosis Supplements. 32:157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d29a3ae0e426746f0aca66f9eb3c094f
https://doi.org/10.1016/j.atherosclerosissup.2018.04.475
https://doi.org/10.1016/j.atherosclerosissup.2018.04.475
Publikováno v:
Atherosclerosis. 210:202-208
Objectives The primary objective was to assess the safety and tolerability of pitavastatin 4mg once daily during 52 weeks treatment. The secondary objectives were to assess the effect on lipid and lipoprotein fractions and ratios, and LDL-C target at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b63037f97ffc1ea4e0d5c688b9507c
https://doi.org/10.1016/j.atherosclerosis.2009.12.009
https://doi.org/10.1016/j.atherosclerosis.2009.12.009
Publikováno v:
Current Medical Research and Opinion. 25:2755-2764
The primary objective of this study was to demonstrate equivalence of pitavastatin compared with simvastatin in the reduction of low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia or combined dyslipidaem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2099d45a17d6210dfb016a8d7b5f9354
https://doi.org/10.1185/03007990903290886
https://doi.org/10.1185/03007990903290886
Publikováno v:
Clinical Lipidology. 4:291-302
Aims: To demonstrate the equivalence of pitavastatin compared with the most commonly used doses of atorvastatin in the reduction of LDL-C in primary hypercholesterolemia or combined dyslipidemia. Secondary objectives included the comparison of pitava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a0c4bb7b1cef8478aa6c5efb900392d
https://doi.org/10.2217/clp.09.20
https://doi.org/10.2217/clp.09.20